Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 10;19(6):3281.
doi: 10.3390/ijerph19063281.

The Impact of Functional Bars and Adapted Physical Activity on Quality of Life in Chronic Kidney Disease: A Pilot Study

Affiliations

The Impact of Functional Bars and Adapted Physical Activity on Quality of Life in Chronic Kidney Disease: A Pilot Study

Elisa Grazioli et al. Int J Environ Res Public Health. .

Abstract

Chronic kidney disease (CKD) represents a public health problem because it is characterized by several comorbidities, including uremic sarcopenia (US), and a poor quality of life. Currently, there are no standardized treatments available to counteract the onset of US but only some possible therapeutic approaches to slow its progression. The aim of this pilot study is to collect descriptive data in order to design a clinical trial based on the power analysis and simple size. The purpose of this pilot study was to evaluate the possible beneficial action induced by the functional anti-inflammatory and antioxidant bars in combination with the adapted physical activity (APA), on the onset and progression of US and other related-CKD comorbidities. We enrolled 21 CKD patients under conservative therapy, divided into four groups: (A) the physical exercise program (PEP), three times a week, in combination with the daily consumption of the two functional bars group; (B) the PEP group; (C) the daily consumption of the two functional bars group; (D) the control group. The duration of the study protocol was 12 weeks. We observed an improvement trend of body composition, blood pressure levels, lipid metabolism, and functional test in A and B groups. These preliminary data would seem to confirm the effectiveness of APA and to demonstrate the additive role of the natural bioactive compound's assumption in countering US and other CKD comorbidities.

Keywords: adapted physical activity; chronic kidney disease; natural bioactive compounds; polyphenols; uremic sarcopenia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Laboratory parameters, tests, and questionnaires performed at the various times of the study. Abbreviations: BIA, bioelectrical impedance analysis; CRP, C-reactive protein; ECG, electrocardiogram; ESR, erythrocyte sedimentation rate; FORD, free oxygen radical defense; FORT, free oxygen radicals test; HDL, high-density lipoproteins; HGS-test, handgrip strength-test; LDL, low-density lipoproteins; PREDIMED, prevención con dieta Mediterránea; QRFT, quadriceps rectus femoris thickness; QRFT, quadriceps vastus intermedius thickness; SF-36, short form-36; SCPT, stair climb power test; SMWT, six-minutes walking test; SPPB, short physical performance battery.
Figure 2
Figure 2
Results of the SPPB (A) and SMWT (B) tests in the various groups. Abbreviations: pt, points; SPPB, short physical performance battery; SMWT, six-minute walking test.

Similar articles

Cited by

References

    1. GBD Chronic Kidney Disease Collaboration Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709–733. doi: 10.1016/S0140-6736(20)30045-3. - DOI - PMC - PubMed
    1. Gagliardi I., Patella G., Michael A., Serra R., Provenzano M., Andreucci M. COVID-19 and the Kidney: From Epidemiology to Clinical Practice. J. Clin. Med. 2020;9:2506. doi: 10.3390/jcm9082506. - DOI - PMC - PubMed
    1. Thompson S., James M., Wiebe N., Hemmelgarn B., Manns B., Klarenbach S., Tonelli M., Alberta Kidney Disease N. Cause of Death in Patients with Reduced Kidney Function. J. Am. Soc. Nephrol. 2015;26:2504–2511. doi: 10.1681/ASN.2014070714. - DOI - PMC - PubMed
    1. Ballew S.H., Matsushita K. Cardiovascular Risk Prediction in CKD. Semin. Nephrol. 2018;38:208–216. doi: 10.1016/j.semnephrol.2018.02.002. - DOI - PubMed
    1. Roshanravan B., Robinson-Cohen C., Patel K.V., Ayers E., Littman A.J., de Boer I.H., Ikizler T.A., Himmelfarb J., Katzel L.I., Kestenbaum B., et al. Association between physical performance and all-cause mortality in CKD. J. Am. Soc. Nephrol. 2013;24:822–830. doi: 10.1681/ASN.2012070702. - DOI - PMC - PubMed